{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:12:19Z","timestamp":1778767939429,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.euo.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:30:47Z","timestamp":1778765447000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Intravesical Therapy for Patients with Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8050-9388","authenticated-orcid":false,"given":"Paolo","family":"Zaurito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Makaroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Dominguez-Escrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Masson-Leconmte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.010_b0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2026.04.010_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2026.04.010_b0035","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466\u20135; discussion 475.","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"10.1016\/j.euo.2026.04.010_b0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jjco\/hyq241","article-title":"Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?","volume":"41","author":"Yuge","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0045","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00345-020-03130-1","article-title":"Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer","volume":"38","author":"Krajewski","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0050","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.04.010_b0055","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clgc.2016.06.014","article-title":"Association between number of endoscopic resections and utilization of bacillus Calmette-Gu\u00e9rin therapy for patients with high-grade, non-muscle-invasive bladder cancer","volume":"15","author":"Lenis","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.04.010_b0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers17020160","article-title":"Symptoms and side effects of Bacille Calmette-Guerin therapy for non-muscle invasive bladder cancer as reported by patients: a systematic review","volume":"17","author":"Lahoud","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2026.04.010_b0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, Phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2025.101198","article-title":"Assessing the clinical efficacy of neoadjuvant intravesical mitomycin C in na\u00efve non-muscle invasive urinary bladder cancer: a systematic review and meta-analysis","volume":"55","author":"Thakur","year":"2025","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.euo.2026.04.010_b0085","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.04.010_b0090","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and Spider: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.euo.2026.04.010_b0095","unstructured":"Rohatgi A. WebPlotDigitizer\u2013extract data from plots, images, and maps. https:\/\/automeris.io\/."},{"key":"10.1016\/j.euo.2026.04.010_b0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/03610918.2011.560732","article-title":"Confidence intervals for survival probabilities: a comparison study","volume":"40","author":"Yuan","year":"2011","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.euo.2026.04.010_b0110","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.04.010_b0115","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.04.010_b0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2025.07.021","article-title":"Guidelines for meta-analyses and systematic reviews in urology","volume":"88","author":"Vickers","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (Master)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0130","unstructured":"R Core Team. R: a Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2022. https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.euo.2026.04.010_b0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000512052","article-title":"Treatment of large non-muscle-invasive bladder cancer: the potential role of neoadjuvant intravesical chemotherapy","volume":"105","author":"Raber","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2026.04.010_b0145","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JU.0000000000003002","article-title":"Clinical efficacy of neoadjuvant intravesical mitomycin-C therapy immediately before transurethral resection of bladder tumor in patients with nonmuscle-invasive bladder cancer: preliminary results of a prospective, randomized Phase II study","volume":"209","author":"Lee","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2026.04.010_b0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","article-title":"Recirculant hyperthermic intravesical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer","volume":"32","author":"Sousa","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2026.04.010_b0165","first-page":"883","article-title":"The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the PRECAVE randomized clinical trial","volume":"74","author":"Carri\u00f3n","year":"2021","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4111\/icu.20230161","article-title":"The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Gu\u00e9rin versus BCG alone in non-muscle-invasive bladder cancer: a randomized controlled trial","volume":"64","author":"El Azab","year":"2023","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0175","doi-asserted-by":"crossref","first-page":"451.e1","DOI":"10.1016\/j.urolonc.2024.06.026","article-title":"Mitomycin C vs. bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center","volume":"42","author":"Scilipoti","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0180","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bju.16780","article-title":"Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study","volume":"136","author":"Longoni","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.04.010_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11255-023-03765-0","article-title":"Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis","volume":"56","author":"You","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euo.2026.04.010_b0190","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urolonc.2022.09.016","article-title":"A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer","volume":"41","author":"Melgarejo-Segura","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.010_b0195","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000538373","article-title":"The efficacy and safety of hyperthermia intravesical chemotherapy in the treatment of non-muscle-invasive bladder cancer: a meta-analysis","volume":"108","author":"Duan","year":"2024","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2026.04.010_b0200","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0205","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-Na\u00efve High-Risk Nonmuscle-Invasive Bladder Cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.010_b0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:30:56Z","timestamp":1778765456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"alternative-id":["S2588931126001197"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Intravesical Therapy for Patients with Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}